SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
Recent Articles
- Innovations in Identity and Biometric Technology Showcased by BIO-key
- Innovative Identity Solutions by BIO-key Unveiled at Major Events
- Economic Impact: Trump's Oil Statement Sends Markets Reeling
- Moon Area School District Chooses Focus School Software Solutions
- Significant Growth in Interbrand's 2025 Best Global Brands List
- RTX Launches Major Expansion of Air and Missile Defense Facility
- China's Commitment to Women's Development: A Global Perspective
- 24X National Exchange Revolutionizes Global Trading Access
- CME Group Launches Dubai Office to Enhance Market Access
- Australian Oilseeds Holdings Experiences Massive Stock Surge
- Cynthia Lummis Champions Bitcoin Energy Argument for USD Security
- Pam Bondi Addresses Meta's Action Against Doxxing of ICE Agents
- HistoIndex Unveils Groundbreaking Fibrosis Diagnostic Innovations
- EyePoint Pharmaceuticals Prices Public Offering for Growth
- MegazoneCloud Achieves Historic ISO/IEC 42001 Certification
- EyePoint Pharmaceuticals Optimizes Capital with New Offering
- Global Helium Corp. Adjusts Shareholders Meeting Procedures
- Bitcoin's Volatile Journey: How Trade Tensions Shape the Market
- Nutex Health's Legal Troubles: A Dive into the Allegations
- Nokia Drives Enhanced Railway Safety Through Advanced Networking Solutions
- Legal Guidance for Investors in Dow Inc. Securities Claims
- KBR Investors Urged to Seek Legal Action Following Share Loss
- Jean Simcox Named Pinnacle Professional Member for Excellence
- Denny LaVé Honored as Pinnacle Professional in Construction
- Jean Simcox: A Pinnacle Professional in Real Estate Excellence
- Introducing the Innovative Yamaha MODX M Synthesizer
- Yamaha's MODX M Synthesizer: A New Era of Musical Innovation
- Cytokinetics Responds to Legal Actions: What Investors Need to Know
- Countdown to the 18th Annual Greenwich CIO Summit Awaits!
- Bunker Hill Mining Corp. Receives Approval for Stock Grants
- Molina Healthcare Class Action Lawsuit: Important Updates
- Investors Urged to Act Fast in Marex Group Lawsuit
- Legal Action on Fluor Corporation: What Investors Need to Know
- Bunker Hill Mining Corp Unveils Exciting Stock Grants Details
- Intel's Ambitious AI Strategy: Launching Crescent Island GPUs
- Investors Alert: Participate in WPP Class Action Lawsuit
- Opportunity for V.F. Corporation Investors in Class Action
- Investigation Alert: Danaher Corporation's Directors Under Scrutiny
- C3.ai Investors Urged to Act Now for Class Action Lawsuit
- Important Legal Updates for V.F. Corporation Investors
- Up-to-the-Minute Analysis of 5 Must-Watch Stocks Today
- Investing in Snap: What Stakeholders Need to Know
- Cathie Wood Makes Bold Investment in DraftKings Amid Market Changes
- Significant Investment for Social Housing Repairs in Canada
- Aegis Resources Ltd. Completes Stock Options Grant to Key Players
- Zefiro's Founder Takes a Stand Against Board Decisions and Claims
- Class Action Lawsuit Opportunity for Lantheus Holdings Investors
- Nona Biosciences Welcomes Dr. Di Hong as New CEO to Drive Growth
- Astellas Shares New VEOZAH Insights at Annual Menopause Event
- Exploring the Growth of Bloom Energy Over the Past Five Years